Edarbi Approved for Treatment of HypertensionLast Updated: February 28, 2011.
MONDAY, Feb. 28 (HealthDay News) -- Edarbi (azilsartan medoxomil) has been approved by the U.S. Food and Drug Administration to treat adults with hypertension.
Clinical trials showed Edarbi was more effective in lowering high blood pressure over 24 hours than two previously FDA-approved drugs, Diovan (valsartan) and Benicar (olmesartan), the agency said in a news release.
Edarbi helps lower blood pressure by blocking the action of angiotensin II, the FDA said. The most common adverse reaction was diarrhea, maker Takeda Pharmaceutical North America said in a statement.
Edarbi has a boxed label warning that it shouldn't be used by women who are pregnant. If a woman becomes pregnant while taking the drug, it should be discontinued as soon as possible, the FDA stressed.
Takeda is based in Deerfield, Ill.
The U.S. National Heart Lung and Blood Institute has more about high blood pressure.
|Previous: Type of Radiation Used Affects Response in Anal Cancer||Next: CROI: Rectal Gel May Guard Against HIV|
Reader comments on this article are listed below. Review our comments policy.